Navigation Links
FDA Submission of B-R-A-H-M-S MR-proANP Kryptor
Date:3/6/2009

HENNIGSDORF, Germany, March 6 /PRNewswire/ -- B-R-A-H-M-S Aktiengesellschaft today announced it has submitted 510(k) file to the U.S. Food and Drug Administration (FDA) to market its patented B-R-A-H-M-S MR-proANP Kryptor Test.

Atrial Natriuretic Peptide (ANP) is predominantly produced in the atrium of the heart and comprises 98% of the natriuretic peptides in the circulation. ANP is involved in natriuresis, diuresis, vasodilation and cardiovascular homeostasis. Although this peptide is unstable, the B-R-A-H-M-S-assay detects the corresponding prohormone fragment: the Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP). In contrast to the mature peptide, MR-proANP is a stable and reliable surrogate measurement of atrial natriuretic peptide levels.

The clinical benefits of MR-proANP were analyzed within an international, multi-center, prospective, multi-marker trial called BACH (Biomarkers in Acute Congestive Heart Failure). Enrolling 1641 patients presenting with shortness of breath to participating emergency rooms the study demonstrated MR-proANP to be a highly useful marker for diagnosing congestive heart failure. Furthermore it provides additional information especially in diagnostically challenging subgroups such as obesity, higher age or renal dysfunction compared to routinely used markers.

First presented at the 2008 ESC Congress and subsequently at the 2008 AHA annual meeting, the results of the BACH-trial confirm the company's commitment to improving healthcare through highly effective biomarker tests and complement the success of the Procalcitonin Kryptor, the company's test for the diagnosis of severe bacterial infections, introduced in the U.S. in early 2008.

B-R-A-H-M-S is a global biotechnology company committed to improving healthcare through the discovery and development of new, innovative biomarkers for the diagnosis, treatment and therapeutic management of life-threatening diseases. With its more than 400 employees, the company's goal is to extend its large portfolio of new biomarker tests for infectious and cardiovascular diseases as well as other clinical applications. B-R-A-H-M-S develops and markets its patent-protected products worldwide to hospitals, laboratories and licensees. B-R-A-H-M-S AG has its headquarters in Hennigsdorf near Berlin, Germany.

B-R-A-H-M-S USA, the wholly-owned subsidiary of B-R-A-H-M-S AG, markets Procalcitonin(R), the company's FDA-cleared marker for sepsis. The B-R-A-H-M-S PCT sensitive Kryptor(R) test enables physicians to determine whether an infection is bacterial or viral in nature and provides actionable information on the severity of a patient's condition less than an hour after a blood sample is drawn.

    For more information, please visithttp://www.brahms-usa.com and
http://www.brahms.de.

    Contact:
    B-R-A-H-M-S USA, Inc.
    Richard Hockins
    +1-410-897-9960
    r.hockins@brahms-usa.com


'/>"/>
SOURCE B-R-A-H-M-S Aktiengesellschaft
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
2. MannKind Updates Status of NDA Submission for AFRESA
3. Kensey Nash Announces IDE Submission for Cartilage Repair Device
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
6. Alfacell Provides ONCONASE(R) NDA Submission Update
7. FDA Reviewing Biomoda Submission for Cancer Screening Study
8. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
9. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
10. Synbiotics Corporation Announces Human Submission for FluDetect(R)
11. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... latest in wound care advancements to physician colleagues, skilled nursing facility medical directors ... "Navigating the Treacherous Waters of Wound Care." , "At many of these conferences ...
Breaking Medicine News(10 mins):